Investing in start-ups
Biocodex has invested in start-ups since 2016 and become a key player in the French biotech ecosystem. We focus mainly on companies developing innovative therapeutics with probiotics or microbial strains that are beneficial to health.
Biocodex invests in MaaT Pharma
Biocodex acquired a stake in MaaT Pharma (Euronext: MAAT) in 2016. MaaT Pharma’s scientific teams harness the potential of the microbiome by developing high-richness, high-diversity microbiome-based therapeutics for cancer patients. Biocodex contributes its 60 years of industrial expertise in strain culture, lyophilization, and oral formulation and supports MaaT Pharma in the clinical development of its two drug candidates (MaaT013, in development for the treatment of graft-versus-host disease, and MaaT033, in development for patients undergoing stem cell transplantation).
MaaT Pharma relies on its powerful AI-driven discovery and analysis platform, gutPrint®, which supports the development of its product portfolio and its expansion to broader indications. This platform helps identify new therapeutic targets, evaluate drug candidates, and pinpoint biomarkers for managing diseases involving the microbiome.
Biocodex invests in Exeliom Biosciences
Biocodex has invested in Exeliom Biosciences since 2018. This company’s mission is to develop a new class of medicines, Live Biotherapeutics, based on the growing understanding of the central role of the microbiota in the immune system. Exeliom Biosciences has developed a mono-strain approach using Faecalibacterium prausnitzii, which it believes could significantly improve the treatment of inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis.
Biocodex invests in GMT Science
GMT Science is an innovative medtech company harnessing standardized, high-resolution stool metagenomics and AI-driven data science to develop in vitro diagnostics (IVD), brought to clinicians via medical laboratories.
It brings together a multidisciplinary team of microbiome experts, clinicians, AI specialists, data scientists and medical software engineers to develop in vitro diagnostics leveraging the gut microbiome.
GMT Science has developed BiomScope®, a proprietary CE-marked IVD software to accurately measure microbial species, genes and functions, outperforming reference metagenomics pipelines.
Its first product, IOScope®, is an in vitro diagnostics predicting the response to immune checkpoint inhibitors (ICI). By predicting the response to ICI, IOScope® allows personalizing treatments, maximizes their benefits and optimizes medical spendings.
The company leverages its collaborations with leading hospitals across Europe and North America and its unique database of over 20,000 curated clinical samples to discover and validate indicationspecific microbiome biomarkers.
Biocodex invests in Kinnov Therapeutics
Biocodex has invested in Kinnov Therapeutics since 2018. Kinnov Therapeutics concentrates its research on the combination of cyproheptadine and prazosin, two molecules that work in synergy to treat addictions.
Kinnov Therapeutics is conducting a Phase II clinical trial to confirm the efficacy of combined cyproheptadine and prazosin in the treatment of alcohol addiction, a field lacking in medical solutions. This project has received funding from the European Union’s Horizon 2020 Research and Innovation program.
Biocodex invests in My Health
My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected based on scientific data, in response to growing consumer demand for solutions to digestive health, women’s health, brain health, joint health and immune system boosting.
